Loading…
Anti-CD37 targeted immunotherapy of B-Cell malignancies
CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the ef...
Saved in:
| Published in: | Biotechnology letters 2018-12, Vol.40 (11-12), p.1459-1466 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c372t-d15d157d5c3100a7d31bf2a31efdf2e024f1f5a8e40f27d4d36bd3bef1d067c43 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c372t-d15d157d5c3100a7d31bf2a31efdf2e024f1f5a8e40f27d4d36bd3bef1d067c43 |
| container_end_page | 1466 |
| container_issue | 11-12 |
| container_start_page | 1459 |
| container_title | Biotechnology letters |
| container_volume | 40 |
| creator | Payandeh, Zahra Noori, Effat Khalesi, Bahman Mard-Soltani, Maysam Abdolalizadeh, Jalal Khalili, Saeed |
| description | CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained. |
| doi_str_mv | 10.1007/s10529-018-2612-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2116652648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2116652648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-d15d157d5c3100a7d31bf2a31efdf2e024f1f5a8e40f27d4d36bd3bef1d067c43</originalsourceid><addsrcrecordid>eNp1kDtPwzAQxy0EoqXwAVhQJGbDnZ3YzVjCU6rEArPlxHZJlUexk4Fvj6sUmJBOuuH-j9OPkEuEGwSQtwEhYzkFXFImkFFxROaYSU6FlOKYzAFTpFmasxk5C2ELALkEeUpmHFjOkedzIlfdUNPinstk0H5jB2uSum3Hrh8-rNe7r6R3yR0tbNMkrW7qTae7qrbhnJw43QR7cdgL8v748FY80_Xr00uxWtOKSzZQg1kcabKKx4-1NBxLxzRH64xjFljq0GV6aVNwTJrUcFEaXlqHBoSsUr4g11Puzvefow2D2vaj72KlYohCZEyky6jCSVX5PgRvndr5utX-SyGoPSo1oVIRldqjUiJ6rg7JY9la8-v4YRMFbBKEeOo21v9V_5_6DUaQcjo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2116652648</pqid></control><display><type>article</type><title>Anti-CD37 targeted immunotherapy of B-Cell malignancies</title><source>Springer Link</source><creator>Payandeh, Zahra ; Noori, Effat ; Khalesi, Bahman ; Mard-Soltani, Maysam ; Abdolalizadeh, Jalal ; Khalili, Saeed</creator><creatorcontrib>Payandeh, Zahra ; Noori, Effat ; Khalesi, Bahman ; Mard-Soltani, Maysam ; Abdolalizadeh, Jalal ; Khalili, Saeed</creatorcontrib><description>CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.</description><identifier>ISSN: 0141-5492</identifier><identifier>EISSN: 1573-6776</identifier><identifier>DOI: 10.1007/s10529-018-2612-6</identifier><identifier>PMID: 30293139</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Antigens, Neoplasm ; Applied Microbiology ; Biochemistry ; Biomedical and Life Sciences ; Biotechnology ; Chronic lymphocytic leukemia ; Clinical trials ; Domains ; Humans ; Immunoglobulin G - therapeutic use ; Immunotherapy ; Leukemia, B-Cell - therapy ; Life Sciences ; Lymphocytes B ; Lymphoma, Non-Hodgkin - therapy ; Medical research ; Microbiology ; Monoclonal antibodies ; Patients ; Proteins ; Recombinant Fusion Proteins - therapeutic use ; Review ; Tetraspanins - antagonists & inhibitors ; Toxicity ; Transmembrane domains</subject><ispartof>Biotechnology letters, 2018-12, Vol.40 (11-12), p.1459-1466</ispartof><rights>Springer Nature B.V. 2018</rights><rights>Biotechnology Letters is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-d15d157d5c3100a7d31bf2a31efdf2e024f1f5a8e40f27d4d36bd3bef1d067c43</citedby><cites>FETCH-LOGICAL-c372t-d15d157d5c3100a7d31bf2a31efdf2e024f1f5a8e40f27d4d36bd3bef1d067c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30293139$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Payandeh, Zahra</creatorcontrib><creatorcontrib>Noori, Effat</creatorcontrib><creatorcontrib>Khalesi, Bahman</creatorcontrib><creatorcontrib>Mard-Soltani, Maysam</creatorcontrib><creatorcontrib>Abdolalizadeh, Jalal</creatorcontrib><creatorcontrib>Khalili, Saeed</creatorcontrib><title>Anti-CD37 targeted immunotherapy of B-Cell malignancies</title><title>Biotechnology letters</title><addtitle>Biotechnol Lett</addtitle><addtitle>Biotechnol Lett</addtitle><description>CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.</description><subject>Antigens, Neoplasm</subject><subject>Applied Microbiology</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biotechnology</subject><subject>Chronic lymphocytic leukemia</subject><subject>Clinical trials</subject><subject>Domains</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunotherapy</subject><subject>Leukemia, B-Cell - therapy</subject><subject>Life Sciences</subject><subject>Lymphocytes B</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Medical research</subject><subject>Microbiology</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Proteins</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Review</subject><subject>Tetraspanins - antagonists & inhibitors</subject><subject>Toxicity</subject><subject>Transmembrane domains</subject><issn>0141-5492</issn><issn>1573-6776</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kDtPwzAQxy0EoqXwAVhQJGbDnZ3YzVjCU6rEArPlxHZJlUexk4Fvj6sUmJBOuuH-j9OPkEuEGwSQtwEhYzkFXFImkFFxROaYSU6FlOKYzAFTpFmasxk5C2ELALkEeUpmHFjOkedzIlfdUNPinstk0H5jB2uSum3Hrh8-rNe7r6R3yR0tbNMkrW7qTae7qrbhnJw43QR7cdgL8v748FY80_Xr00uxWtOKSzZQg1kcabKKx4-1NBxLxzRH64xjFljq0GV6aVNwTJrUcFEaXlqHBoSsUr4g11Puzvefow2D2vaj72KlYohCZEyky6jCSVX5PgRvndr5utX-SyGoPSo1oVIRldqjUiJ6rg7JY9la8-v4YRMFbBKEeOo21v9V_5_6DUaQcjo</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Payandeh, Zahra</creator><creator>Noori, Effat</creator><creator>Khalesi, Bahman</creator><creator>Mard-Soltani, Maysam</creator><creator>Abdolalizadeh, Jalal</creator><creator>Khalili, Saeed</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QR</scope><scope>7T7</scope><scope>7TB</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>L7M</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope></search><sort><creationdate>20181201</creationdate><title>Anti-CD37 targeted immunotherapy of B-Cell malignancies</title><author>Payandeh, Zahra ; Noori, Effat ; Khalesi, Bahman ; Mard-Soltani, Maysam ; Abdolalizadeh, Jalal ; Khalili, Saeed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-d15d157d5c3100a7d31bf2a31efdf2e024f1f5a8e40f27d4d36bd3bef1d067c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens, Neoplasm</topic><topic>Applied Microbiology</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biotechnology</topic><topic>Chronic lymphocytic leukemia</topic><topic>Clinical trials</topic><topic>Domains</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunotherapy</topic><topic>Leukemia, B-Cell - therapy</topic><topic>Life Sciences</topic><topic>Lymphocytes B</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Medical research</topic><topic>Microbiology</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Proteins</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Review</topic><topic>Tetraspanins - antagonists & inhibitors</topic><topic>Toxicity</topic><topic>Transmembrane domains</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Payandeh, Zahra</creatorcontrib><creatorcontrib>Noori, Effat</creatorcontrib><creatorcontrib>Khalesi, Bahman</creatorcontrib><creatorcontrib>Mard-Soltani, Maysam</creatorcontrib><creatorcontrib>Abdolalizadeh, Jalal</creatorcontrib><creatorcontrib>Khalili, Saeed</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest Engineering Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>ProQuest Central Basic</collection><jtitle>Biotechnology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Payandeh, Zahra</au><au>Noori, Effat</au><au>Khalesi, Bahman</au><au>Mard-Soltani, Maysam</au><au>Abdolalizadeh, Jalal</au><au>Khalili, Saeed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-CD37 targeted immunotherapy of B-Cell malignancies</atitle><jtitle>Biotechnology letters</jtitle><stitle>Biotechnol Lett</stitle><addtitle>Biotechnol Lett</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>40</volume><issue>11-12</issue><spage>1459</spage><epage>1466</epage><pages>1459-1466</pages><issn>0141-5492</issn><eissn>1573-6776</eissn><abstract>CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>30293139</pmid><doi>10.1007/s10529-018-2612-6</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0141-5492 |
| ispartof | Biotechnology letters, 2018-12, Vol.40 (11-12), p.1459-1466 |
| issn | 0141-5492 1573-6776 |
| language | eng |
| recordid | cdi_proquest_journals_2116652648 |
| source | Springer Link |
| subjects | Antigens, Neoplasm Applied Microbiology Biochemistry Biomedical and Life Sciences Biotechnology Chronic lymphocytic leukemia Clinical trials Domains Humans Immunoglobulin G - therapeutic use Immunotherapy Leukemia, B-Cell - therapy Life Sciences Lymphocytes B Lymphoma, Non-Hodgkin - therapy Medical research Microbiology Monoclonal antibodies Patients Proteins Recombinant Fusion Proteins - therapeutic use Review Tetraspanins - antagonists & inhibitors Toxicity Transmembrane domains |
| title | Anti-CD37 targeted immunotherapy of B-Cell malignancies |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A47%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-CD37%20targeted%20immunotherapy%20of%20B-Cell%20malignancies&rft.jtitle=Biotechnology%20letters&rft.au=Payandeh,%20Zahra&rft.date=2018-12-01&rft.volume=40&rft.issue=11-12&rft.spage=1459&rft.epage=1466&rft.pages=1459-1466&rft.issn=0141-5492&rft.eissn=1573-6776&rft_id=info:doi/10.1007/s10529-018-2612-6&rft_dat=%3Cproquest_cross%3E2116652648%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-d15d157d5c3100a7d31bf2a31efdf2e024f1f5a8e40f27d4d36bd3bef1d067c43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2116652648&rft_id=info:pmid/30293139&rfr_iscdi=true |